EE05453B1 - Protsess asetidinoonvahehendite valmistamiseks - Google Patents
Protsess asetidinoonvahehendite valmistamiseksInfo
- Publication number
- EE05453B1 EE05453B1 EEP200300464A EEP200300464A EE05453B1 EE 05453 B1 EE05453 B1 EE 05453B1 EE P200300464 A EEP200300464 A EE P200300464A EE P200300464 A EEP200300464 A EE P200300464A EE 05453 B1 EE05453 B1 EE 05453B1
- Authority
- EE
- Estonia
- Prior art keywords
- preparation
- azetidinone intermediates
- compound
- azetidinone
- intermediates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- General Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27928801P | 2001-03-28 | 2001-03-28 | |
PCT/US2002/009123 WO2002079174A2 (en) | 2001-03-28 | 2002-03-25 | Enantioselective synthesis of azetidinone intermediate compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
EE200300464A EE200300464A (et) | 2003-12-15 |
EE05453B1 true EE05453B1 (et) | 2011-08-15 |
Family
ID=23068350
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200300464A EE05453B1 (et) | 2001-03-28 | 2002-03-25 | Protsess asetidinoonvahehendite valmistamiseks |
Country Status (29)
Country | Link |
---|---|
US (1) | US6627757B2 (et) |
EP (1) | EP1373230B1 (et) |
JP (1) | JP4145663B2 (et) |
KR (1) | KR100590342B1 (et) |
CN (1) | CN1275949C (et) |
AT (1) | ATE305459T1 (et) |
AU (1) | AU2002258605B2 (et) |
BG (1) | BG66189B1 (et) |
BR (1) | BRPI0208384B1 (et) |
CA (1) | CA2442219C (et) |
CZ (1) | CZ304929B6 (et) |
DE (1) | DE60206365T2 (et) |
DK (1) | DK1373230T3 (et) |
EA (1) | EA006898B1 (et) |
EE (1) | EE05453B1 (et) |
ES (1) | ES2245733T3 (et) |
HK (1) | HK1057546A1 (et) |
HR (1) | HRP20030760B1 (et) |
HU (1) | HU230229B1 (et) |
IL (2) | IL157552A0 (et) |
MX (1) | MXPA03008803A (et) |
NZ (1) | NZ527852A (et) |
PL (1) | PL205952B1 (et) |
RS (1) | RS50386B (et) |
SI (1) | SI1373230T1 (et) |
SK (1) | SK287408B6 (et) |
UA (1) | UA75644C2 (et) |
WO (1) | WO2002079174A2 (et) |
ZA (1) | ZA200306612B (et) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
US20040132058A1 (en) | 2002-07-19 | 2004-07-08 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
US7135556B2 (en) | 2002-07-19 | 2006-11-14 | Schering Corporation | NPC1L1 (NPC3) and methods of use thereof |
AR040588A1 (es) | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
EP1918000A2 (en) | 2003-11-05 | 2008-05-07 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
US7871998B2 (en) | 2003-12-23 | 2011-01-18 | Astrazeneca Ab | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity |
EP1723414A4 (en) | 2004-01-16 | 2008-03-26 | Merck & Co Inc | NPC1L1 (NPC3) AND METHOD FOR IDENTIFYING ITS LIGANDS |
JP2008514718A (ja) * | 2004-09-29 | 2008-05-08 | シェーリング コーポレイション | 置換アゼチドノンおよびcb1アンタゴニストの組み合わせ |
CA2589483C (en) | 2004-12-03 | 2013-10-29 | Schering Corporation | Substituted piperazines as cb1 antagonists |
US8308559B2 (en) * | 2007-05-07 | 2012-11-13 | Jay Chun | Paradise box gaming system |
TW200726746A (en) * | 2005-05-06 | 2007-07-16 | Microbia Inc | Processes for production of 4-biphenylylazetidin-2-ones |
KR20080023296A (ko) * | 2005-05-09 | 2008-03-13 | 마이크로비아 인코포레이티드 | 유기금속 벤젠포스포네이트 커플링제 |
EA200702464A1 (ru) * | 2005-05-11 | 2008-04-28 | Майкробиа, Инк. | Способы получения фенольных 4-бифенилилазетидин-2-онов |
JP2008545700A (ja) * | 2005-05-25 | 2008-12-18 | マイクロビア インコーポレーテッド | 4−(ビフェニリル)アゼチジン−2−オンホスホン酸類の製造方法 |
KR20080021082A (ko) * | 2005-06-20 | 2008-03-06 | 쉐링 코포레이션 | 히스타민 h3 길항제로서 유용한 피페리딘 유도체 |
SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
MX2007005493A (es) * | 2005-09-08 | 2007-09-11 | Teva Pharma | Procesos para la preparacion de (3r,4s)-4-((4-benciloxi)fenil)-1- (4-fluorofenil)-3-((s)-3-(4-fluorofenil)-3-hidroxipropil-2- azetidinona, un intermedio para la sintesis de ezetimibe. |
HU0501164D0 (en) * | 2005-12-20 | 2006-02-28 | Richter Gedeon Vegyeszet | New industrial process for the production of ezetimibe |
BRPI0706623A2 (pt) | 2006-01-18 | 2011-04-12 | Schering Corp | moduladores de receptor canabinóide |
CA2642388C (en) * | 2006-02-16 | 2013-11-05 | Kotobuki Pharmaceutical Co., Ltd. | Process for preparing optically active alcohols |
WO2007100807A2 (en) * | 2006-02-24 | 2007-09-07 | Schering Corporation | Npc1l1 orthologues |
AR060623A1 (es) | 2006-04-27 | 2008-07-02 | Astrazeneca Ab | Compuestos derivados de 2-azetidinona y un metodo de preparacion |
EP2059241A1 (en) * | 2006-09-05 | 2009-05-20 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
WO2008130616A2 (en) * | 2007-04-19 | 2008-10-30 | Schering Corporation | Diaryl morpholines as cb1 modulators |
US20090047716A1 (en) * | 2007-06-07 | 2009-02-19 | Nurit Perlman | Reduction processes for the preparation of ezetimibe |
CN101790521A (zh) * | 2007-06-28 | 2010-07-28 | 英特维特国际股份有限公司 | 作为cb1拮抗剂的取代哌嗪 |
MX2010000334A (es) * | 2007-06-28 | 2010-04-22 | Intervet Int Bv | Piperazinas sustituidas como antagonistas de cannabinoides 1. |
WO2009032264A1 (en) * | 2007-08-30 | 2009-03-12 | Teva Pharmaceutical Industries Ltd. | Processes for preparing intermediates of ezetimibe by microbial reduction |
US20090312302A1 (en) * | 2008-06-17 | 2009-12-17 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders |
EP2329014B1 (en) | 2008-08-29 | 2014-10-22 | Codexis, Inc. | Ketoreductase polypeptides for the stereoselective production of (4s)-3[(5s)-5(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one |
EP2414529A2 (en) | 2009-04-01 | 2012-02-08 | Matrix Laboratories Ltd | Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe |
EP2467473B1 (en) | 2009-08-19 | 2016-03-23 | Codexis, Inc. | Ketoreductase polypeptides for the preparation of phenylephrine |
HUE026367T2 (en) | 2010-05-04 | 2016-06-28 | Codexis Inc | Biocatalysts of ezetimibe synthesis |
WO2012155932A1 (en) | 2011-05-17 | 2012-11-22 | Pharmathen S.A. | Improved process for the preparation of ezetimibe |
CN111518046B (zh) * | 2020-06-04 | 2022-04-15 | 中山奕安泰医药科技有限公司 | 依泽替米贝中间体及依泽替米贝的制备方法 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2046823A1 (de) | 1970-09-23 | 1972-03-30 | Farbwerke Hoechst AG vormals Meister Lucius & Brüning, 6000 Frankfurt | Neue Azetidinone-(2) und Verfahren zu deren Herstellung |
JPS5628057A (en) | 1979-08-13 | 1981-03-19 | Isuzu Motors Ltd | Front cab suspension device for tiltable cab |
DE3006193C2 (de) | 1980-02-19 | 1984-04-12 | Siemens AG, 1000 Berlin und 8000 München | Elektrische Anschlußverbindung der Elektroden eines Gasentladungs-Überspannungsableiters |
US4680391A (en) | 1983-12-01 | 1987-07-14 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
JPS61121479A (ja) | 1984-11-19 | 1986-06-09 | Mitsubishi Electric Corp | 太陽電池素子 |
JPS61180212A (ja) | 1985-02-06 | 1986-08-12 | Asahi Optical Co Ltd | 後絞り型写真レンズ |
JPS62219681A (ja) | 1986-03-20 | 1987-09-26 | Toshiba Corp | 光信号処理素子の基準光源 |
EP0266896B1 (en) | 1986-10-03 | 1992-08-05 | Eli Lilly And Company | 7-( (meta-substituted) phenylglycine) 1-carba-1-dethiacephalosporins |
US4803266A (en) | 1986-10-17 | 1989-02-07 | Taisho Pharmaceutical Co., Ltd. | 3-Oxoalkylidene-2-azetidinone derivatives |
EP0333268A1 (en) | 1988-03-18 | 1989-09-20 | Merck & Co. Inc. | Process for synthesis of a chiral 3-beta hydrogen (3R) 4-aroyloxy azetidinone |
NZ228600A (en) | 1988-04-11 | 1992-02-25 | Merck & Co Inc | 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives |
US4952689A (en) | 1988-10-20 | 1990-08-28 | Taisho Pharmaceutical Co., Ltd. | 3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation |
US4876365A (en) | 1988-12-05 | 1989-10-24 | Schering Corporation | Intermediate compounds for preparing penems and carbapenems |
FR2640621B1 (fr) | 1988-12-19 | 1992-10-30 | Centre Nat Rech Scient | N-aryl-azetidinones, leur procede de preparation et leur utilisation comme inhibiteurs des elastases |
US4983597A (en) | 1989-08-31 | 1991-01-08 | Merck & Co., Inc. | Beta-lactams as anticholesterolemic agents |
US5120729A (en) | 1990-06-20 | 1992-06-09 | Merck & Co., Inc. | Beta-lactams as antihypercholesterolemics |
IL99658A0 (en) | 1990-10-15 | 1992-08-18 | Merck & Co Inc | Substituted azetidinones and pharmaceutical compositions containing them |
JPH04356195A (ja) | 1991-05-30 | 1992-12-09 | Kyowa Hakko Kogyo Co Ltd | アゼチジノン誘導体の製造法 |
US5688787A (en) | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof |
US5561227A (en) | 1991-07-23 | 1996-10-01 | Schering Corporation | Process for the stereospecific synthesis of azetidinones |
DE69222532T2 (de) | 1991-07-23 | 1998-02-26 | Schering Corp | Substituierte beta-lactam-verbindungen als hypocholesterolemische mittel und verfahren zu deren herstellung |
US5688785A (en) | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
LT3300B (en) | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
LT3595B (en) | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
ATE205475T1 (de) | 1993-07-09 | 2001-09-15 | Schering Corp | Verfahren zur herstellung von azetidinonen |
US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5627176A (en) | 1994-03-25 | 1997-05-06 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
US5624920A (en) | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5633246A (en) | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5656624A (en) | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
US5631635A (en) * | 1995-05-08 | 1997-05-20 | Motorola, Inc. | Message/response tracking system and method for a two-way selective call receiving device |
US5618707A (en) | 1996-01-04 | 1997-04-08 | Schering Corporation | Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof |
NZ321766A (en) | 1995-10-31 | 1999-07-29 | Schering Corp | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
AU7472896A (en) | 1995-11-02 | 1997-05-22 | Schering Corporation | Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon |
EP0865429A1 (en) | 1995-12-08 | 1998-09-23 | Smithkline Beecham Plc | Azetidinone compounds for the treatment of atherosclerosis |
HUP9901359A3 (en) | 1996-04-26 | 2000-03-28 | Smithkline Beecham Plc | Azetidinone derivatives for the treatment of atherosclerosis, process for their producing and pharmaceutical compositions containing them |
US5886171A (en) | 1996-05-31 | 1999-03-23 | Schering Corporation | 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones |
US5739321A (en) | 1996-05-31 | 1998-04-14 | Schering Corporation | 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones |
GB9611947D0 (en) | 1996-06-07 | 1996-08-07 | Glaxo Group Ltd | Medicaments |
AU3667297A (en) | 1996-07-09 | 1998-02-02 | Merck & Co., Inc. | Therapy for combined hyperlipidemia |
AU4050797A (en) | 1996-08-02 | 1998-02-25 | Ligand Pharmaceuticals Incorporated | Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators |
CN1233954A (zh) | 1996-10-01 | 1999-11-03 | 西马实验室股份有限公司 | 掩盖味道的微胶囊组合物及其制备方法 |
US5756470A (en) | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
FR2758461A1 (fr) | 1997-01-17 | 1998-07-24 | Pharma Pass | Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation |
DK1021405T3 (da) | 1997-10-07 | 2003-02-03 | Boehringer Ingelheim Ca Ltd | Azetidinonderivater til behandling af HCMV-infektioner |
US6133001A (en) | 1998-02-23 | 2000-10-17 | Schering Corporation | Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone |
US5919672A (en) | 1998-10-02 | 1999-07-06 | Schering Corporation | Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone |
CA2353981C (en) | 1998-12-07 | 2005-04-26 | Schering Corporation | Process for the synthesis of azetidinones |
US6207822B1 (en) * | 1998-12-07 | 2001-03-27 | Schering Corporation | Process for the synthesis of azetidinones |
CA2367289C (en) | 1999-04-05 | 2008-02-12 | Schering Corporation | Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(r)-[3(s)-hydroxy-3-(4-fluorophenyl)propyl)]-4(s)-(4-hydroxyphenyl)-2-azetidinone |
AU4343500A (en) | 1999-04-16 | 2000-11-02 | Schering Corporation | Use of azetidinone compounds |
SI1593670T1 (sl) | 2000-12-20 | 2007-12-31 | Schering Corp | S hidroksi substituirani 2-azetidinoni, uporabni kot sredstva za zniĹľevanje holesterola |
ES2277890T3 (es) | 2000-12-21 | 2007-08-01 | Sanofi-Aventis Deutschland Gmbh | Nuevas difenilazetidinonas, procedimiento para su preparacion, medicamentos que contienen estos compuestos y su uso para el tratamiento de trastornos del metabolismo de lipidos. |
TWI291957B (en) | 2001-02-23 | 2008-01-01 | Kotobuki Pharmaceutical Co Ltd | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same |
-
2002
- 2002-03-25 JP JP2002577801A patent/JP4145663B2/ja not_active Expired - Lifetime
- 2002-03-25 ES ES02728561T patent/ES2245733T3/es not_active Expired - Lifetime
- 2002-03-25 UA UA2003109666A patent/UA75644C2/uk unknown
- 2002-03-25 US US10/105,710 patent/US6627757B2/en not_active Expired - Lifetime
- 2002-03-25 MX MXPA03008803A patent/MXPA03008803A/es active IP Right Grant
- 2002-03-25 EP EP02728561A patent/EP1373230B1/en not_active Expired - Lifetime
- 2002-03-25 PL PL363864A patent/PL205952B1/pl unknown
- 2002-03-25 KR KR1020037012486A patent/KR100590342B1/ko active IP Right Grant
- 2002-03-25 SI SI200230193T patent/SI1373230T1/sl unknown
- 2002-03-25 SK SK1186-2003A patent/SK287408B6/sk unknown
- 2002-03-25 CA CA002442219A patent/CA2442219C/en not_active Expired - Lifetime
- 2002-03-25 AT AT02728561T patent/ATE305459T1/de active
- 2002-03-25 WO PCT/US2002/009123 patent/WO2002079174A2/en active IP Right Grant
- 2002-03-25 HU HU0303526A patent/HU230229B1/hu unknown
- 2002-03-25 RS YUP-748/03A patent/RS50386B/sr unknown
- 2002-03-25 EA EA200300970A patent/EA006898B1/ru not_active IP Right Cessation
- 2002-03-25 BR BRPI0208384A patent/BRPI0208384B1/pt active IP Right Grant
- 2002-03-25 AU AU2002258605A patent/AU2002258605B2/en not_active Expired
- 2002-03-25 CZ CZ2003-2610A patent/CZ304929B6/cs not_active IP Right Cessation
- 2002-03-25 DE DE60206365T patent/DE60206365T2/de not_active Expired - Lifetime
- 2002-03-25 NZ NZ527852A patent/NZ527852A/en not_active IP Right Cessation
- 2002-03-25 CN CNB028075374A patent/CN1275949C/zh not_active Expired - Lifetime
- 2002-03-25 EE EEP200300464A patent/EE05453B1/et unknown
- 2002-03-25 DK DK02728561T patent/DK1373230T3/da active
- 2002-03-25 IL IL15755202A patent/IL157552A0/xx unknown
-
2003
- 2003-08-24 IL IL157552A patent/IL157552A/en unknown
- 2003-08-25 ZA ZA200306612A patent/ZA200306612B/en unknown
- 2003-09-09 BG BG108168A patent/BG66189B1/bg unknown
- 2003-09-19 HR HR20030760A patent/HRP20030760B1/xx not_active IP Right Cessation
-
2004
- 2004-01-07 HK HK04100111A patent/HK1057546A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE05453B1 (et) | Protsess asetidinoonvahehendite valmistamiseks | |
MXPA04001323A (es) | Dihidro-3-halo-1h-pirazol-5-carboxilatos sustituidos, su preparacion y uso. | |
ATE297203T1 (de) | Antithrombotische mitteln | |
NZ514711A (en) | Compounds useful as anti-inflammatory agents | |
ATE306261T1 (de) | Antithrombosemittel | |
BG106340A (en) | Substituted oxoazaheterocyclyl compounds | |
IL173377A0 (en) | Compounds for the treatment of metabolic disorders | |
GB0127903D0 (en) | Improvements relating to organic compounds | |
HUP0301076A2 (hu) | Linezolid II kristályforma és előállítása | |
MY138263A (en) | Therapeutic chroman compounds | |
AU2001284190A1 (en) | Benzylidene thiazolidinediones and their use as antimycotic agents | |
DE60114640D1 (en) | Antithrombosemittel | |
MY139228A (en) | Imidazolinylmethyl aralkylsulfonamides | |
MXPA04005151A (es) | Compuestos terapeuticos. | |
IL156768A0 (en) | Process for preparing (+/-) trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidine | |
ATE419238T1 (de) | Arylsulfanyl und heteroarylsulfanyl-derivate zur behandlung von schmerz | |
MXPA03002493A (es) | Proceso eficiente para preparacion de un inhibidor del factor xa. | |
DE60043228D1 (de) | Herstellungsverfahren von 2-cyanopyridinen | |
YU62302A (sh) | Postupak za izradu jedinjenja 2-(4-alkil-1-piperazinil)- benzaldehida i benzilidenila | |
SE0103646D0 (sv) | Therapeutic chroman compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC1A | Change of owner name | ||
HC1A | Change of owner name |